

## Short communication

Dopamine D<sub>3</sub> receptor density elevation in aged  
Fischer-344 × Brown-Norway (F1) rats

David R. Wallace, Rosemarie M. Booze \*

*University of Kentucky Medical Center, Department of Pharmacology, and Sanders-Brown Center on Aging, Lexington, KY 40536-0084, USA*

Received 26 February 1996; revised 6 May 1996; accepted 7 May 1996

---

**Abstract**

The density of dopamine D<sub>3</sub> receptors was determined in young (4-month-old) and aged (37-month-old) Fischer-344 × Brown-Norway (F1) male rats using the putative D<sub>3</sub> receptor-preferring agonist, [<sup>3</sup>H](+)-7-hydroxy-2-(*N,N*-di-*n*-propylamino)tetralin ([<sup>3</sup>H](+)-7-OH-DPAT). In the presence of the non-hydrolyzable GTP analog, 5'-guanylylimidodiphosphate (Gpp(NH)p), the density of dopamine D<sub>3</sub> receptors in the striatum and nucleus accumbens was significantly increased (29–102%, respectively) in aged Fischer-344 × Brown-Norway (F1) rats compared to young adults. These findings suggest that dopaminergic activity in aged rats is compromised by increased D<sub>3</sub> receptor density, resulting in altered striatal/nucleus accumbens function via presynaptic or postsynaptic modifications.

**Keywords:** Striatum; Nucleus accumbens; Basal forebrain

---

**1. Introduction**

The aging process produces widespread alterations in dopaminergic receptors which result in profound cognitive and motor changes. In general, D<sub>2</sub> dopamine receptor density is decreased in most regions in an age-related fashion (Sakata et al., 1992). The mechanism for this dopamine receptor loss is unclear, but may involve receptor loss due to cell death and/or decreased protein synthesis capabilities. Although Sakata et al. (1992) reported no change in D<sub>2</sub> receptor mRNA expression, it was suggested that an alteration in post-transcriptional processing occurred during the aging process. Other investigators have reported that expression of D<sub>2</sub> receptor mRNA is reduced in aged animals (Valerio et al., 1994). Therefore, reductions in D<sub>2</sub> receptor density might be due to decreased production of receptor protein or the formation of non-functional receptor variants following errors in post-transcriptional processing.

Few studies have addressed age-related changes in the dopamine D<sub>3</sub> receptor, a member of the novel 'D<sub>2</sub>-like' receptor group. The D<sub>3</sub> receptor has been cloned and characterized (Sokoloff et al., 1990; Bouthenet et al.,

1991). The distribution of the D<sub>3</sub> receptor protein was initially reported to be restricted primarily to mesolimbic areas (Sokoloff et al., 1990; Bouthenet et al., 1991), but was subsequently demonstrated to constitute a small number of 'D<sub>2</sub>-like' receptor binding sites in the striatum (Wallace and Booze, 1995). Valerio et al. (1994) reported that the expression of D<sub>3</sub> receptor mRNA in aged rats was reduced in the olfactory tubercle, a region with a dense D<sub>3</sub> receptor population, but was unchanged in the striatum. Schmauss et al. (1993) demonstrated that mRNA expression for the D<sub>3</sub> receptor is reduced in parietal and motor cortices of schizophrenic and Alzheimer's disease (mean age > 70 years old) patients. The D<sub>3</sub> receptor has also been implicated as a potential locus for the treatment of neuropsychiatric disorders (Sokoloff et al., 1990), thus the D<sub>3</sub> receptor is a candidate for therapeutic treatment of neuropsychiatric disorders associated with the aging process. Additional studies investigating the function of the D<sub>3</sub> receptor during the aging process are critical for greater understanding of deficits associated with the aging process and disease.

**2. Materials and methods****2.1. Animals**

Adult (4-month-old) and aged (37-month-old) male Fischer-344 × Brown-Norway (F1) hybrid rats were main-

---

\* Corresponding author. University of Kentucky Medical Center, Department of Pharmacology, MS305, 800 Rose Street, Lexington, KY 40536-0084, USA. Tel.: +1 606 323 6507; fax: +1 606 257 4716; e-mail: booze@pop.uky.edu

tained on a 12-h photoperiod with food and water available ad libitum. This hybrid strain of rat is currently the model of choice for aging studies due to their increased longevity and lack of age-related pathology (Sprott, 1991). Animals were killed by rapid decapitation, brain tissue was removed and subsequently frozen in liquid nitrogen. Tissues (striatum and nucleus accumbens, including olfactory tubercle) were stored at  $-80^{\circ}\text{C}$  until analysis.

## 2.2. Tissue preparation and receptor binding

Striatal and nucleus accumbens (containing olfactory tubercles) tissue homogenates were prepared as previously described (Wallace and Booze, 1995). In brief, binding to the dopamine  $\text{D}_3$  receptor was performed by addition of tissue homogenate (900  $\mu\text{l}$ ; 250–300 v/w) to 50  $\mu\text{l}$  [ $^3\text{H}$ ](+)-7-hydroxy-2-(*N,N*-di-*n*-propylamino)tetralin ([ $^3\text{H}$ ](+)-7-OH-DPAT; 10 nM; Amersham, Arlington, IL, USA; 155 Ci/mmol) and 50  $\mu\text{l}$  of buffer (total binding) or 1  $\mu\text{M}$  dopamine (non-specific binding). The density of  $\text{D}_3$  sites labeled by 10 nM [ $^3\text{H}$ ](+)-7-OH-DPAT would represent > 90% of the total density of  $\text{D}_3$  receptors based on fractional occupancy ( $[^*L]/K_d + [^*L]$ ). To prevent the labeling of high-affinity  $\text{D}_2$  sites by [ $^3\text{H}$ ](+)-7-OH-DPAT, 10  $\mu\text{M}$  Gpp(NH)p was included in the assay buffer. Other investigators have reported that both 0.2 mM (Gonzalez and Sibley, 1995) and 0.1 mM (Levesque et al., 1992) Gpp(NH)p effectively abolish [ $^3\text{H}$ ]7-OH-DPAT binding to high-affinity  $\text{D}_2$  receptors. We have determined that 10 mM Gpp(NH)p and 0.3 mM GTP also prevent labeling of high-affinity  $\text{D}_2$  receptors (data not shown). Binding was performed in the presence of 0.5  $\mu\text{M}$  carbetapentane to prevent [ $^3\text{H}$ ](+)-7-OH-DPAT binding to  $\sigma_1$  receptors (Wallace and Booze, 1995). Incubations were carried out to equilibrium (90 min) at room temperature ( $21 \pm 2^{\circ}\text{C}$ ) and terminated by rapid filtration onto GF/B filters (pre-soaked for 2 h in 0.3% polyethyleneimine) under reduced pressure by a Brandel Tissue Harvester. Radioligand bound was determined by scintillation spectrophotometry (efficiency of 45%).

## 2.3. Chemicals and statistics

Carbetapentane and ( $\pm$ )-7-OH-DPAT were obtained from Research Biochemicals (Natick, MA, USA). All other chemicals were purchased from either Sigma Chemicals (St. Louis, MO, USA) or Fisher Scientific (Springfield, NJ, USA). Data were analyzed as fmol/mg protein using two-way (age  $\times$  region) ANOVA.

## 3. Results

In 4-month-old rats, the density of  $\text{D}_3$  receptors labeled by 10 nM [ $^3\text{H}$ ](+)-7-OH-DPAT in the presence of 10  $\mu\text{M}$  Gpp(NH)p exhibited significant [ $F(1,20) = 8.37$ ;  $P < 0.01$ ]




Fig. 1. The density of  $\text{D}_3$  receptors ( $n = 4$ ) was determined with 10 nM [ $^3\text{H}$ ](+)-7-OH-DPAT in the presence of 10  $\mu\text{M}$  Gpp(NH)p to prevent the labeling of high-affinity  $\text{D}_2$  receptors. Binding was initiated by the addition of radioligand and allowed to proceed at room temperature until equilibrium (90 min).  $\text{D}_3$  receptor density was significantly upregulated in 37-month-old rats compared to 4-month-old rats in both the striatum and nucleus accumbens. The distribution of  $\text{D}_3$  receptors demonstrated significant effects of region as well as age, but no interaction between age and region was observed.

regional variation and was in excellent agreement with the values reported by Levesque et al. (1992). In 4-month-old animals, the density of  $\text{D}_3$  receptors in the nucleus accumbens was 2.33-fold greater than the  $\text{D}_3$  receptor density in the striatum (Fig. 1). In 37-month-old animals, this difference was reduced to 1.49-fold greater in the nucleus accumbens compared to the striatum. There was a significant effect of age since the density of  $\text{D}_3$  receptors was elevated [ $F(1,20) = 4.48$ ;  $P < 0.05$ ] in both the striatum (102%) and nucleus accumbens (29%) in 37-month-old rats compared to 4-month-old rats (Fig. 1). The density of dopamine  $\text{D}_2$  receptors was unchanged in both the striatum and nucleus accumbens from aged rats (data not shown).

## 4. Discussion

In the present study, the observation of significant upregulation of  $\text{D}_3$  receptors in both the striatum and nucleus accumbens in 37-month-old rats is a striking contrast to the age-related downregulation observed in  $\text{D}_2$  receptor density (Sakata et al., 1992). The  $\text{D}_3$  dopamine receptor exhibits the characteristics of a presynaptic autoreceptor in the striatum (Meller et al., 1993) and nucleus accumbens (Gilbert et al., 1995). These findings suggest that the  $\text{D}_3$  receptor may have an important function both in motor control (striatum) and limbic (nucleus accumbens) response. Alterations in  $\text{D}_3$  receptor density or function might have an important role in the motor and cognitive decline associated with the aging process.

Preliminary studies suggest the  $\text{D}_3$  receptor mRNA expression in the cortex may be reduced in disorders associated with the aging process (Schmauss et al., 1993), although  $\text{D}_3$  receptor mRNA expression in the striatum is

unchanged (Valerio et al., 1994). Therefore, elevated D<sub>3</sub> receptor binding in the striatum and nucleus would represent an increased functional D<sub>3</sub> receptor in these regions. Our findings suggest a unique function for the D<sub>3</sub> receptor during the aging process, perhaps serving to compensate for the loss of D<sub>2</sub> receptors in the striatum. Collectively, these data support a hypothesis for age-related alterations in dopamine D<sub>3</sub> receptors in both the striatum and nucleus accumbens. Development of therapeutic compounds which selectively modulate the D<sub>3</sub> receptor may result in uniquely efficacious treatments for the cognitive and motor dysfunction commonly observed during the aging process.

### Acknowledgements

This work was supported by grants DA06638, DA09160, AG10836 and AG10747 (to R.M.B.) and postdoctoral training grant AG00242 (to D.R.W) from the National Institutes of Health.

### References

- Bouthenet, M.-L., E. Souil, M.-P. Martres, P. Sokoloff, B. Giros and J.-C. Schwartz, 1991, Localization of dopamine D<sub>3</sub> receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D<sub>2</sub> receptor mRNA, *Brain Res.* 564, 203.
- Gilbert, D.B., J. Millar and S.J. Cooper, 1995, The putative dopamine D<sub>3</sub> agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum, *Brain Res.* 681, 1.
- Gonzalez, A.M. and D.R. Sibley, 1995, [<sup>3</sup>H]7-OH-DPAT is capable of labeling dopamine D<sub>2</sub> as well as D<sub>3</sub> receptors, *Eur. J. Pharmacol.* 272, R1.
- Levesque, D., J. Diaz, C. Pilon, M.-P. Martres, B. Giros, E. Souil, D. Schott, J.-L. Morgat, J.-C. Schwartz and P. Sokoloff, 1992, Identification, characterization, and localization of the dopamine D<sub>3</sub> receptor in rat brain using 7-[<sup>3</sup>H]hydroxy-*N,N*-di-*n*-propyl-2-aminotetralin, *Proc. Natl. Acad. Sci. USA* 89, 8155.
- Meller, E., K. Bohmker, M. Goldstein and D.A. Basham, 1993, Evidence that striatal synthesis-inhibiting autoreceptors are dopamine D<sub>3</sub> receptors, *Eur. J. Pharmacol.* 249, R9.
- Sakata, M., S.M. Farooqui and C. Prasad, 1992, Post-transcriptional regulation of loss of rat striatal D<sub>2</sub> dopamine receptor during aging, *Brain Res.* 575, 309.
- Schmauss, C., V. Haroutunian, K.L. Davis and M. Davidson, 1993, Selective loss of dopamine D<sub>3</sub>-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia, *Proc. Natl. Acad. Sci. USA* 90, 8942.
- Sokoloff, P., B. Giros, M.-P. Martres, M.-L. Bouthenet and J.-C. Schwartz, 1990, Molecular cloning and characterization of a novel dopamine receptor (D<sub>3</sub>) as a target for neuroleptics, *Nature (London)* 347, 146.
- Sprott, R.L., 1991, Development of animal models of aging at the National Institute on Aging, *Neurobiol. Aging* 12, 635.
- Valerio, A., M. Belloni, M.L. Gorno, C. Tinti, M. Memo and P. Spano, 1994, Dopamine D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> receptor mRNA levels in rat brain and pituitary during aging, *Neurobiol. Aging* 15, 713.
- Wallace, D.R. and R.M. Booze, 1995, Identification of D<sub>3</sub> and  $\sigma$  receptors in the rat striatum and nucleus accumbens using ( $\pm$ )-7-hydroxy-*N,N*-di-*n*-[<sup>3</sup>H]propyl-2-aminotetralin and carbetapentane, *J. Neurochem.* 64, 700.